Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein.

Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been used as a live bacterial vaccine to immunize more than two billion people against tuberculosis. In an attempt to use this vaccinal strain as a vehicle for protective antigens, the human immunodeficiency virus type 1 gene encoding the Nef protein was cloned in a mycobacteria-Escherichia coli shuttle plasmid and transferred into BCG. The nef gene was expressed under the control of an expression cassette carrying the promoter of the groES/groEL1 operon from Streptomyces albus and a synthetic ribosome-binding site. Lymph node cells from mice immunized with BCG-nef proliferated vigorously in response to purified Nef protein. This first report of a proliferative response suggests that recombinant BCG strains may be used to immunize against pathogens for which T-cell-mediated responses are important for protection.

[1]  B. Guy,et al.  Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins , 1989, Journal of virology.

[2]  J. Moniz-Pereira,et al.  Complete nucleotide sequence of pAL5000, a plasmid from Mycobacterium fortuitum. , 1988, Gene.

[3]  R. Young,et al.  Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines , 1991, Nature.

[4]  W. Jacobs,et al.  Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guérin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  F. Heffron,et al.  Induction of Salmonella stress proteins upon infection of macrophages. , 1990, Science.

[6]  B. Bloom.  Learning from leprosy: a perspective on immunology and the Third World. , 1986, Journal of immunology.

[7]  B. Gicquel,et al.  Functional analysis of pAL5000, a plasmid from Mycobacterium fortuitum: construction of a "mini" mycobacterium-Escherichia coli shuttle vector , 1990, Journal of bacteriology.

[8]  W. Jacobs,et al.  New use of BCG for recombinant vaccines , 1991, Nature.

[9]  B. Guy,et al.  HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product , 1987, Nature.

[10]  W. Huse,et al.  Lambda ZAP: a bacteriophage lambda expression vector with in vivo excision properties. , 1988, Nucleic acids research.

[11]  W. Szybalski,et al.  A comprehensive molecular map of bacteriophage lambda. , 1979, Gene.

[12]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[13]  Juliano Timm,et al.  Transposition of an antibiotic resistance element in mycobacteria , 1990, Nature.

[14]  R. Desrosiers,et al.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS , 1991, Cell.

[15]  J. Garcia,et al.  Serine phosphorylation-independent downregulation of cell-surface CD4 by nef , 1991, Nature.

[16]  B. Guy,et al.  An antigenic peptide of the HIV‐1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA‐B , 1989, European journal of immunology.

[17]  W. Bullock.  XL1-Blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection. , 1987 .

[18]  C. Kirkpatrick,et al.  The immunology of mycobacterial diseases. , 1986, The American review of respiratory disease.

[19]  P. Lagrange,et al.  The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. , 1988, Journal of biological standardization.

[20]  K. Kobayashi,et al.  Establishment of a foreign antigen secretion system in mycobacteria , 1990, Infection and immunity.

[21]  W. Jacobs,et al.  Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis , 1990, Molecular microbiology.